Dyne Therapeutics (DYN) Total Current Liabilities (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Total Current Liabilities data on file, last reported at $51.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 51.26% year-over-year to $51.2 million in Q1 2026; TTM through Mar 2026 was $51.2 million, a 51.26% increase from a year earlier, with the FY2025 full-year figure at $50.6 million, up 19.8% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $51.2 million, up from $50.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for DYN reached as high as $59.8 million in Q3 2025 and fell as low as $20.2 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $35.2 million across 5 years, with a median of $29.8 million in 2024.
• On a YoY basis, Total Current Liabilities climbed as much as 81.91% in 2023 and fell as far as 21.08% in 2023.
• Year by year, Total Current Liabilities stood at $28.1 million in 2022, then surged by 81.91% to $51.1 million in 2023, then dropped by 17.3% to $42.3 million in 2024, then advanced by 19.8% to $50.6 million in 2025, then advanced by 1.23% to $51.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $51.2 million in Q1 2026, $50.6 million in Q4 2025, and $59.8 million in Q3 2025.